ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Other Events
Item 8.01Other Events.

Attached as Exhibit 99.1 is a presentation that Eleven Biotherapeutics, Inc. will post on its website on October 20, 2017 and may use from time to time in presentations or discussions with investors, analysts and other parties.

Item 9.01Financial Statements and Exhibits

(d) Exhibits.

The exhibit filed as part of this Current Report on Form 8-K is set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

Eleven Biotherapeutics, Inc. Exhibit
EX-99.1 2 exhibit991.htm EXHIBIT 99.1 exhibit991 © 2017 Eleven Biotherapeutics. All rights reserved. © 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION™   © 2017 Eleven Biotherapeutics. All rights reserved. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements,…
To view the full exhibit click here

About ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO)

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).